Morgan Stanley
MS
$214.38
+0.81%
Morgan Stanley is a global financial services firm operating across institutional securities, wealth management, and investment management, with a significant presence in investment banking and trading. It is a market leader in wealth management, boasting $9.3 trillion in client assets, and has transformed into a bank holding company with a top-10 deposit franchise. The current investor narrative centers on the firm's ability to sustain robust revenue growth driven by strong capital markets activity and wealth management expansion, while managing risks from market volatility and regulatory changes. Recent headlines highlight a rebound in investment banking fees and the impact of Fed stress tests on capital returns, fueling optimism about the stock's earnings trajectory.…
MS
Morgan Stanley
$214.38
Related headlines
Investment Opinion: Should I buy MS Today?
Rating: Buy. Morgan Stanley is a high-quality financial franchise with accelerating revenue growth (22.4% YoY) and a forward PE of 15.96x, which is attractive given expected EPS growth. The average analyst target of $236.62 implies 8.7% upside, and the PEG ratio of 0.60 suggests the stock is undervalued relative to its growth prospects. The firm's wealth management segment provides a stable revenue base, while investment banking and trading are benefiting from a robust capital markets environment.
Sign up to view all
MS 12-Month Price Forecast
The AI model assesses Morgan Stanley as a bullish opportunity over the next 12 months, driven by strong earnings momentum and reasonable valuation. The accelerating revenue growth and improving profitability provide a solid foundation, while the PEG ratio suggests the market has not fully priced in future earnings expansion. However, the high beta and cyclicality warrant caution, as a market downturn could quickly reverse gains. The stance would be upgraded to high confidence if revenue growth sustains above 20% and the stock breaks above its 52-week high, while a downgrade to neutral would occur if growth decelerates below 10% or the stock falls below $200.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Morgan Stanley's 12-month outlook, with a consensus price target around $237.33 and implied upside of +10.7% versus the current price.
Average Target
$237.33
0 analysts
Implied Upside
+10.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$184 - $262
Analyst target range
Morgan Stanley is covered by 21 analysts, with a consensus recommendation leaning bullish, as recent ratings include multiple 'Buy' and 'Outperform' actions from firms like UBS, B of A Securities, and Evercore ISI, though some 'Neutral' ratings from Goldman Sachs and JP Morgan temper the outlook. The average target price is $236.62, implying approximately 8.7% upside from the current price of $217.72, with a target range from $184.00 (low) to $262.00 (high). The high target suggests expectations of continued earnings growth and multiple expansion, while the low target reflects concerns about market downturns or regulatory pressures. The spread between high and low targets indicates moderate uncertainty, but the recent pattern of ratings shows more upgrades than downgrades, signaling positive sentiment among analysts.
Bulls vs Bears: MS Investment Factors
Morgan Stanley presents a compelling bull case driven by accelerating revenue growth (22.4% YoY), strong profitability (net margin 16.2%), and an attractive PEG of 0.60, supported by a bullish analyst consensus. However, bears point to high leverage (D/E 4.26), negative FCF, and the stock's proximity to 52-week highs, which could limit near-term upside. The central tension is whether the current capital markets boom is sustainable; if it continues, the stock is undervalued, but a sharp slowdown could expose the firm's cyclicality and leverage. Currently, the evidence slightly favors the bulls given the strong earnings momentum and reasonable forward PE, but investors should monitor market conditions closely.
Bullish
- Robust Revenue Acceleration: Q2 2026 revenue surged 22.4% YoY to $34.47B, accelerating from 17.6% growth in Q1 2026 and 8.7% in Q2 2025, driven by strong capital markets and wealth management. This multi-quarter acceleration signals a powerful cyclical upswing.
- Attractive Valuation with PEG of 0.60: With a trailing PE of 17.17x and forward PE of 15.96x, the stock trades at a discount to its growth rate, as evidenced by a PEG ratio of 0.60. This suggests the market is underpricing Morgan Stanley's earnings expansion potential.
- Strong Earnings Growth and Profitability: Q2 2026 net income rose to $5.58B (EPS $3.46), up from $3.54B (EPS $2.15) a year ago, with net margin expanding to 16.2% from 12.6%. ROE stands at a solid 15.1%, reflecting efficient capital deployment.
- Analyst Consensus Bullish with 8.7% Upside: The average analyst target of $236.62 implies 8.7% upside from the current price of $217.72, with a high target of $262. Recent ratings from UBS, BofA, and Evercore ISI are Buy/Outperform, indicating positive sentiment.
Bearish
- High Debt-to-Equity Ratio of 4.26: Morgan Stanley's debt-to-equity ratio of 4.26x is elevated, reflecting its reliance on leverage typical of large banks. This amplifies vulnerability to credit market disruptions and rising funding costs.
- Negative Free Cash Flow: Trailing twelve-month free cash flow is -$1.05B, indicating the firm is consuming cash despite strong earnings. This could constrain capital returns or signal aggressive reinvestment needs.
- Trading Near 52-Week Highs: At $217.72, the stock is 93% of its 52-week range (high $232.25), leaving limited upside if momentum stalls. The 1-month price change of -0.25% and relative strength of -0.30 vs. S&P suggest short-term consolidation.
- Market Cyclicality and Beta of 1.21: With a beta of 1.21, MS is more volatile than the market, and its investment banking and trading revenues are highly sensitive to economic cycles. A downturn could sharply reduce earnings, as seen in past recessions.
MS Technical Analysis
Morgan Stanley's stock has been in a strong uptrend over the past year, with a 1-year price change of +44.6%, significantly outperforming the S&P 500's +18.7% gain. The current price of $217.72 sits at approximately 93% of its 52-week range (between $146.29 low and $232.25 high), indicating the stock is trading near its highs, reflecting robust momentum but also potential overextension. The 6-month price change of +35.8% underscores the sustained bullish trend, with the stock having rallied from around $160 in March to recent levels above $217.
Beta
1.21
1.21x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$152-$232
Price range past year
Annual Return
+37.0%
Cumulative gain past year
| Period | MS Return | S&P 500 |
|---|---|---|
| 1m | -1.5% | -1.1% |
| 3m | +0.2% | +3.0% |
| 6m | +38.4% | +15.4% |
| 1y | +37.0% | +16.2% |
| ytd | +17.9% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MS Fundamental Analysis
Morgan Stanley's revenue trajectory is strongly positive, with the most recent quarter (Q2 2026) reporting revenue of $34.47 billion, a 22.4% year-over-year increase, accelerating from the 17.6% growth seen in Q1 2026. This growth is driven by robust performance across all segments, with Wealth Management contributing $8.43 billion, Institutional Securities $7.93 billion, and Investment Management $1.72 billion in the latest quarter. The multi-quarter trend shows consistent acceleration from $28.16 billion in Q2 2025 to $34.47 billion in Q2 2026, indicating a strong cyclical upswing in capital markets and sustained fee-based revenue growth.
Quarterly Revenue
$34.5B
2026-06
Revenue YoY Growth
+22.4%
YoY Comparison
Gross Margin
61.7%
Latest Quarter
Free Cash Flow
$-1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MS Overvalued?
Given Morgan Stanley's positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 17.17x, while the forward PE is 15.96x, with the forward discount implying the market expects continued earnings growth. The stock's PEG ratio of 0.60 suggests that the stock is undervalued relative to its growth rate, indicating attractive value for the expected earnings expansion.
PE
17.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 11x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. Morgan Stanley's debt-to-equity ratio of 4.26x is high, reflecting significant leverage that could amplify losses during credit stress. The firm's negative free cash flow of -$1.05B TTM, despite strong net income, suggests potential liquidity constraints or heavy reinvestment, which may limit capital return flexibility. Revenue concentration in capital markets activities, which are cyclical, means a downturn could sharply reduce earnings, as evidenced by the 2022 slowdown. Additionally, the operating margin of 19.1% is sensitive to compensation costs and market-making losses, which can fluctuate widely quarter to quarter.
FAQ
The key risks include: 1) High leverage (D/E 4.26) which could magnify losses in a credit crunch; 2) Cyclicality of capital markets revenue, which could decline sharply in a recession; 3) Negative free cash flow (-$1.05B TTM) that may limit capital returns; 4) Regulatory changes that could increase capital requirements. The most severe risk is a prolonged market downturn, which could reduce earnings by over 30% and push the stock to the low target of $184, a 15% downside from current levels.
The 12-month forecast is moderately bullish, with a base case target of $236.62 (8.7% upside) and a bull case target of $262 (20% upside), which has a 30% probability. The bear case target is $184 (15% downside), with a 20% probability. The most likely scenario (50% probability) is that the stock trades in the $225-$240 range, supported by continued revenue growth and stable market conditions. Key drivers include capital markets activity and wealth management expansion.
MS is currently undervalued relative to its growth prospects, as indicated by a PEG ratio of 0.60. The trailing PE of 17.17x and forward PE of 15.96x are reasonable for a company with expected EPS growth of over 20%. Compared to its own history, the stock trades at a slight premium to its 5-year average PE, but the accelerating earnings justify this. The market is pricing in continued growth, but not excessively, leaving room for upside if the company beats expectations.
Yes, MS appears to be a good buy for investors with a growth-oriented portfolio, given its strong revenue acceleration (22.4% YoY) and attractive valuation (PEG 0.60). The average analyst target of $236.62 implies 8.7% upside, and the firm's wealth management business provides stability. However, the stock is near its 52-week high, so short-term pullbacks are possible. It is best suited for investors willing to hold through market cycles, as the high beta (1.21) and leverage (D/E 4.26) can amplify losses in downturns.
MS is suitable for both, but it is better aligned with long-term investing given its cyclical nature and high beta (1.21). Short-term traders may find opportunities in its volatility, but the stock's performance is highly dependent on market conditions. For long-term investors, the firm's wealth management franchise and strong market position provide a solid foundation for sustained growth. A minimum holding period of 3-5 years is recommended to ride out market cycles and benefit from earnings growth, with the stock offering a dividend yield of 2.36% as a modest income component.